Seaport Therapeutics
Seaport Therapeutics doses first patient in trial of GlyphAllo for depression
July 25, 2025Research and Development Psychiatry, Seaport Therapeutics, clinical trial, major depressive disorder, mental health, neuropsychiatric conditions
Seaport Therapeutics has dosed its first patient in its phase 2b BUOY-1 study of GlyphAllo (SPT-300), an oral prodrug of …
David Wheadon appointed to board of directors at Seaport Therapeutics
August 14, 2024Corporate, Seaport Therapeutics, appointment
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Latest content
MedPharm appoints Jason Mieding as chief operating officer
November 8, 2026
Coriolis Pharma appoints Teun van der Heide as CEO
November 7, 2026
The evidence bar impacting UK medical cannabis access
November 6, 2026
